Indian Pharma Sector: Generics Ka Zamana Gaya? Innovation Banega Future!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Indian Pharma Sector: Generics Ka Zamana Gaya? Innovation Banega Future!
Overview

Pharma industry ke top leaders ne ekdum clear kar diya hai – ab sirf generics par depend karna mushkil hai. Sector ko grow karna hai toh 'innovation' par focus karna ab choice nahi, zaroori ho gaya hai. China se badhti competition ke beech, R&D mein investment aur naye drugs banana bahut important hai.

Pharma industry ke bade players ne kahin na kahin yeh confirm kar diya hai ki ab woh time gaya jab sirf generics se kaam chalta tha. Jab "Made in India: The Story of Desh Bandhu Gupta, Lupin and Indian Pharma" book launch ho rahi thi, tab seasoned leaders ne zor dekar kaha ki sustainable growth ke liye genuine innovation zaroori hai. Dilip Shanghvi (Sun Pharma) ne bhi bataya kaise unki company ne pehle ek drug se start karke ab generics aur novel therapies dono mein paisa laga rahi hai, jisme R&D par kafi investment hai jiska outcome uncertain ho sakta hai.

Yeh discussion is reality par bhi light daalti hai ki India ne China ke rapid innovation ko underestimate kiya hai. GV Prasad ne pointed out kiya ki China ab sirf low-cost supplier nahi raha, balki ek tough competitor ban gaya hai. Unka regulatory framework bhi evolve hua hai aur state ka support bhi hai, jiski wajah se woh value chain mein kafi upar aa gaye hain aur India ke liye ek asli challenge pesh kar rahe hain.

Current India pharma market mein lagbhag 97% toh off-patent generics hi hain. Lekin segments jaise biosimilars mein already branding aur credibility chahiye hoti hai, jo market ke badalte dynamics dikhata hai. Lupin ki Vinita Gupta ne stressed kiya ki agli dashak mein India ko strategic pivot karna hoga India-focused innovation aur cost-effective drug development par. India ke vast patient base ko clinical trials ke liye use karna aur locally relevant R&D par focus karna achhi opportunities hain. Par iske liye kuch critical factors hain: better regulatory support, R&D mein acquisitions, aur sabse zaroori, doctors, investors aur companies ka trust jeetna jald se jald.

Y.K. Hamied, jinhone India ki generics revolution mein bada naam kamaya tha, woh abhi bhi access aur affordability par focus kar rahe hain. Unhone yaad dilaya kaise unhone monopolies ke khilaf fight kiya aur affordable HIV/AIDS drugs supply kiye. Unka kehna hai ki generics toh theek hain, par India ki asli innovation tabhi hogi jab medical community Indian novel drugs ko accept karegi. Toh yahi asli challenge hai ki kaise groundbreaking research aur 'pharmacy of the world' wala ethos dono ko maintain karein.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.